A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab. - Yanazume S; Kobayashi Y; Kirita Y; Kitazono I; Nagata C; Kozai A; Tanimoto A; Kobayashi H (The journal of obstetrics and gynaecology research, 2025)